EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational study.

Marco Bolchini, Giulia Ceccardi, Francesca Schiano di Cola, Michele Di Pasquale, Renata Rao, Alessandro Padovani

Neurological Sciences · 2025-09 · 46 (9) · 4515-4526

DOI: 10.1007/s10072-025-08372-8 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neurological Sciences, online erschienen am 21.07.2025. Verfasst von Marco Bolchini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. marco.bolchini1@gmail.com. Hauptthemen laut MEDLINE: Migraine Disorders, Mood Disorders, Antibodies, Monoclonal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Migraine is frequently associated with psychiatric comorbidities, especially anxiety and depressive disorders, with related worse clinical outcome and chronicisation. Aim of the study was to assess the effectiveness of anti-CGRP antibodies in alleviating migraine-related symptoms and comorbid anxiety and depressive symptoms. METHODS: Retrospective observational study including 206 migraine out-patients in treatment with anti-CGRP antibodies. Beck Depression Inventory (BDI) scale assessing depressive symptoms and Zung Anxiety Scale rating anxiety manifestations, were adopted. Patients were divided into two groups based on the severity of mood disturbances according to BDI score. Effectiveness outcomes (monthly headache days (MHDs), monthly migraine days (MMDs), analgesic consumption, Numerical Rating Scale (NRS), Migraine Disability Assessment (MIDAS) score, Headache Impact Test (HIT-6) score) and self-assessment anxiety and depression scales (BDI, Zung) were analysed after 3 and 6 months of treatment. RESULTS: Effectiveness outcomes showed a significant clinical improvement at T3 (ΔMHD - 9.99 ± 7.82 in Group 1, -10.82 ± 7.62 in Group 2) and T6 (MHD - 10.30 ± 7.41 in Group 1, -10.61 ± 7.87 in Group 2), irrespective of the presence of associated mood symptoms. Treatment resulted in a notable improvement in anxiety and depressive manifestations, with significant reduction in BDI and Zung scales at T3 (ΔBDI - 1.30 ± 3.74 in Group 1, -6.35 ± 11.34 in Group 2) and T6 (ΔBDI - 1.67 ± 4.77 in Group 1, -8.06 ± 10.35 in Group 2). CONCLUSIONS: This study corroborates the effectiveness of anti-CGRP antibody treatment in migraine patients, irrespective of the presence of comorbid mood-related symptoms. Furthermore, the persistently favourable outcome in mood symptom severity and intensity throughout the course of treatment substantiates the beneficial impact of this therapeutic approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersMood DisordersAntibodies, MonoclonalHumansMaleFemaleAdultRetrospective StudiesMiddle AgedTreatment OutcomePsychiatric Status Rating Scales

Stichwörter der Autor:innen

Anti-CGRP monoclonal antibodiesAnxiety disordersCGRPDepressive disordersMigraineMood disorders

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. marco.bolchini1@gmail.com.
  • Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy. marco.bolchini1@gmail.com.
  • Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Neurology Unit, Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia Hospital, Brescia, Italy.
  • Brain Health Center, University of Brescia, Brescia, Italy.

Zitieren

APA

Bolchini, M., Ceccardi, G., Schiano di Cola, F., Di Pasquale, M., Rao, R., & Padovani, A. (2025). Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational study. Neurological Sciences, 46(9), 4515-4526. https://doi.org/10.1007/s10072-025-08372-8

Vancouver

Bolchini M, Ceccardi G, Schiano di Cola F, Di Pasquale M, Rao R, Padovani A. Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational study. Neurological Sciences. 2025;46(9):4515-4526. doi:10.1007/s10072-025-08372-8

BibTeX
@article{Bolchini2025,
  author = {Bolchini, Marco and Ceccardi, Giulia and Schiano di Cola, Francesca and Di Pasquale, Michele and Rao, Renata and Padovani, Alessandro},
  title = {Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational study},
  journal = {Neurological Sciences},
  year = {2025},
  volume = {46},
  number = {9},
  pages = {4515--4526},
  doi = {10.1007/s10072-025-08372-8}
}
Kostenlos starten →